← Leaderboards
Richard Childs
Heart, Lung, And Blood Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Heart, Lung, And Blood Institute
Same institution · by research overlap
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingTransplantationDoseSafetyT-LymphocyteInsightStem Cell TransplantProgramsClinical TrialsEnrollmentAntigensPharmaceutical PreparationsCohortBaseRenal Cell CarcinomaTumor AntigensAdultAllogenicClinical ResearchResearch PersonnelTransplant RecipientsFutureCancer ImmunotherapyRecovery
Grant awards (40)
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$3,423,644
ZIA · FY2025 · HL · contact PI
Fostamatinib to Treat Post-Transplant Immune-mediated Cytopenias$180,192
ZIA · FY2025 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$4,926,222
ZIA · FY2024 · HL · contact PI
Fostamatinib to Treat Post-Transplant Immune-mediated Cytopenias$259,275
ZIA · FY2024 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$4,208,801
ZIA · FY2023 · HL · contact PI
Bronchiectasis and chronic airway infection$2,404,445
ZIA · FY2023 · HL · contact PI
A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19.$420,880
ZIA · FY2023 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$3,264,185
ZIA · FY2022 · HL · contact PI
A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19.$829,193
ZIA · FY2022 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$1,570,973
ZIA · FY2021 · HL · contact PI
A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19.$392,743
ZIA · FY2021 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$3,038,595
ZIA · FY2020 · HL · contact PI
A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19.$759,649
ZIA · FY2020 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$3,775,841
ZIA · FY2019 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$229,171
ZIA · FY2019 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$4,077,456
ZIA · FY2018 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$190,606
ZIA · FY2018 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$2,719,866
ZIA · FY2016 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$479,976
ZIA · FY2016 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$2,561,153
ZIA · FY2015 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$451,968
ZIA · FY2015 · HL · contact PI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders$2,767,364
ZIA · FY2014 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$488,358
ZIA · FY2014 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$2,610,373
ZIA · FY2013 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$465,506
ZIA · FY2013 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$2,609,499
ZIA · FY2012 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$460,500
ZIA · FY2012 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$2,693,826
ZIA · FY2011 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$475,381
ZIA · FY2011 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$2,915,077
ZIA · FY2010 · HL · contact PI
Cyclosporine Inhalation Solution (CIS) treatment of Bronchiolitis Obliterans$323,897
ZIA · FY2010 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$2,961,826
ZIA · FY2009 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$3,075,283
Z01 · FY2008 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders$3,465,155
Z01 · FY2007 · HL · contact PI
Allogeneic Immunotherapy for cancer and nonmalignant hem$0
Z01 · FY2006 · HL · contact PI
Allogeneic Immunotherapy$0
Z01 · FY2005 · HL
Allogeneic Immunotherapy$0
Z01 · FY2004 · HL
Allogeneic Immunotherapy$0
Z01 · FY2003 · HL
Allogeneic Immunotherapy$0
Z01 · FY2001 · HL
ALLOGENEIC IMMUNOTHERAPY$0
Z01 · FY2000 · HL